TABLE 4.
Time to Treatment Failure According to EGFRFISH, HER2 FISH, EGFR Mutation and KRAS Mutation Status
| Molecular marker | Categories | Patients | TTF after Gefitinib (Days) Median |
p | |
|---|---|---|---|---|---|
| n | % | ||||
| EGFR | Positive (+) | 29 | 66 | 169 | 0.722 |
| Negative (−) | 15 | 34 | 97 | ||
| HER2 | Positive (+) | 23 | 53 | 121 | 0.1815 |
| Negative (−) | 21 | 47 | 144 | ||
| EGFR and HER2 | +/+ | 19 | 43 | 169 | 0.0179 |
| +/− | 10 | 23 | 118 | ||
| −/+ | 4 | 9 | 56 | ||
| −/− | 11 | 25 | 144 | ||
| EGFR mutation | Positive (+) | 27 | 61 | 311 | <0.0001 |
| Negative (−) | 17 | 39 | 83 | ||
| EGFR FISH and EGFR mutation | +/+ | 22 | 50 | 182 | <0.0001 |
| +/− | 7 | 16 | 67 | ||
| −/+ | 5 | 11 | 916 | ||
| −/− | 10 | 23 | 83 | ||
| KRAS mutation | Positive (+) | 5 | 12 | 87 | 0.0248 |
| Negative (−) | 36 | 88 | 146 | ||
| EGFR FISH and KRAS mutation | +/+ | 1 | 2 | 113 | 0.0767 |
| +/− | 25 | 61 | 169 | ||
| −/+ | 4 | 10 | 57 | ||
| −/− | 11 | 25 | 144 | ||
FISH, fluorescence in situ hybridization; EGFR, epidermal growth factor receptor; TTF, time to treatment failure.